Controlled Inhalation of THC-Predominant Cannabis Flos Improves Quality of Sleep, General Mood, and Severity of PTSD Symptoms in UK Civilians

Attend a 28-minute webinar examining clinical research on THC-predominant cannabis flower for PTSD treatment in UK civilians. Learn about a comprehensive analysis of data from the UK patient registry T21, which utilized validated questionnaires to assess patient-reported outcome measures (PROMs) for health-related quality of life, mood and anxiety levels, sleep quality, and PTSD-specific symptoms. Discover the methodology behind studying patients with confirmed PTSD diagnoses who received prescriptions for chemotype 1 (THC-predominant) cannabis flower, with data collected at baseline and 3-month follow-up periods. Explore the clinical findings demonstrating improvements in sleep quality, general mood, and severity of PTSD symptoms through controlled inhalation methods. Gain insights from Dr. Guillermo Moreno-Sanz, a neuroscientist with over 20 years of cannabinoid research experience, who serves as Scientific Director of Khiron Europe and Leva Clinic, specializing in cannabis-based medicinal products and digital pain management interventions. Access PACE continuing education credits upon completion through Labroots' accredited platform, with credits available until April 2026.